En route to Dallas and just an hour out of Arkansas, Lesley Murphy got a call.
She had been tested about a week before for a genetic mutation that would make her more susceptible to breast and ovarian cancer. And, as it turned out, she had the mutation.
She didn't have either cancer, but, at 29, she found herself weighing her options: go in every six months for screenings, take medicine or undergo a preventive double mastectomy. She had some three hours to go to get to Dallas, where, coincidentally, she had an appointment with her gynecologist.
"I spent a lot of that -- probably at least an hour and a half -- telling nobody," Murphy said. "I was like listening to music and just thinking."
Studies have found that more women are choosing preventive mastectomies. Actress Angelina Jolie drew attention to the procedure in 2013 when she had a mastectomy after learning of her susceptibility to breast and ovarian cancer. The studies vary in the rates of women undergoing the surgical procedure, but most show percentages now in the low teens compared with the 2 percent to 4 percent range in the late 1990s and early 2000s.
Mastectomies can reduce breast cancer recurrence to 1 percent, said Dr. Daniela Ochoa, a breast surgical oncologist at the University of Arkansas for Medical Sciences, Little Rock.
"We take out all the breast tissue that we can see and identify grossly and anatomically with our eyeballs, but we can't say that at a teeny tiny cell level, we got every cell," she said. "So that's why we can't completely eliminate the possibility that there may be something down the road, but it's certainly the most aggressive thing that you could do to decrease your risk."
Murphy's test results came nearly three years after her mother, Martha Murphy, was diagnosed with breast cancer. An unlikely candidate, Martha Murphy had no cancers in her family history, was healthy, exercised regularly, ate well. Unable to come to terms with the diagnosis, she eventually got a genetic test -- the first in her family -- showing she, too, had the genetic mutation, called BRCA-2, predisposing her to breast and ovarian cancers.
In short order, Martha Murphy opted for a double mastectomy, a reconstruction and later an oophorectomy, the removal of the ovaries.
Her two other daughters took a genetic test later that year: one had the mutation, the other didn't. Lesley Murphy would be the tiebreaker.
Bachelor, Argentina
A Fort Smith native, Lesley Murphy graduated from the University of Georgia and worked in Atlanta and Washington, D.C. In the nation's capital, she took a hiatus from her job at a Democratic consulting firm to compete with 25 other women on ABC's show The Bachelor. She didn't find love on the show.
But after the television stint, Lesley Murphy moved to Argentina with her boyfriend at the time and worked as a marketing manager for a luxury hospitality company. She had been thinking of ways to take advantage of her following -- she has 66,284 followers on Twitter, 224,000 on Instagram and 7,652 on Facebook -- from the show, and nothing had come together, she said.
She spent her time there traveling throughout South America, documenting her travels along the way. She decided to trade in her job to be a professional travel blogger, living out of a suitcase -- albeit, a large one.
On March 10, 2014, Lesley Murphy was in her Argentina apartment when her mom and dad called, breaking the news of Martha Murphy's diagnosis.
The parents reassured their three daughters that Martha Murphy found the tumor early and all would be OK. She had consulted two doctors, both of whom had recommended surgery to remove the tumor and 30 rounds of radiation. One of the doctors, an oncologist and family friend, also had recommended a genetic test.
For Martha Murphy, finding the genetic mutation was like finding a needle in a haystack, said Dr. Kent McKelvey, the director of Adult and Cancer Genetics Services at UAMS.
"It would be like, you know, you're sitting in the cancer institute, and there's a lot of rooms in the cancer institute," he said. "You know in one of the rooms, there's the needle that you're looking for. In her mom, we looked through every room, and we found where the needle was."
Martha Murphy tested positive for the BRCA-2 gene mutation.
Days later, with two months until her oldest daughter's wedding, she had a double mastectomy at UAMS. By the May 31, 2014, wedding, she was on the dance floor.
hereditary risk
If an average woman has an 11 percent risk of breast cancer, those with BRCA-1 may have up to eight times the risk, and those with BRCA-2 have about four or five times the risk, McKelvey said.
Cancer occurs because of changes in DNA, which happen because of bad luck, environmental exposures or heredity, said McKelvey, also an associate professor in UAMS' College of Medicine. Most patients get it because of a combination of bad luck and environmental exposures, including hormone-replacement therapies for post-menopausal symptoms and lifestyle choices, such as not eating well, said Ochoa, the breast surgeon.
In Lesley Murphy's case, the major risk factor was hereditary, McKelvey said.
Genetic tests -- like those the Murphys took -- have increased over the years: just over 1,000 tests were ordered in 2012, and now the number is closer to 50,000 a year, according to the Genetic Testing Registry. Some companies are now offering genetic tests for a slew of predispositions, though McKelvey had a warning.
"You don't just order a genetic test because there are implications for you, for your future health care and for your family," he said. "People need to know what they're getting. I'd say it's important to have pre-test counseling and post-test counseling."
UAMS is the only health care facility that offers cancer genetics in the state -- hundreds of genes are predisposed to about 50 cancer syndromes, he said -- and McKelvey's office includes genetic counseling. One of his genetic counselors called Lesley Murphy on her drive to Dallas in mid-February this year, confirming the gene mutation and setting another appointment with McKelvey nearly two months later.
Hers had been an easier find because they knew what to test for and where to find it, McKelvey said.
Thinking over her options, Lesley Murphy ruled out the regular screenings -- getting a breast MRI every six months and a mammogram every six months -- almost immediately.
She figured she could have the procedure done at any time. But once she got to her gynecologist's appointment in Dallas, the doctor said, "You do not have to do this, but in my mind, what's the point of hanging on to something that's potentially very cancerous?"
Lesley Murphy thought it over for a few more days: she would be gone all of March for work, and the gynecologist was right. She called McKelvey's office to schedule an earlier appointment. Afterward, she marked April 11 as the date for her first-ever surgery.
She spent March traveling to Colorado, the United Kingdom, Finland and Canada. She worked out and did yoga.
On March 8 -- International Women's Day -- on "a horrid eight-hour layover in Germany," she shared with the world her genetic test results.
"I wanted to be a voice for other people who were going through the same thing," she said," even just thinking about it or even just starting the conversation for families or a friend to get tested."
She prepared herself mentally, and before she knew it, it was April 11.
"I remember going to sleep that night and getting pretty sentimental because it was my last night with the old me," she said, "and the next day was going to be completely different."
3-month process
The procedure takes out the breast tissue down to the pectoral muscle, said Ochoa, the breast surgeon and assistant professor in UAMS' College of Medicine. Expanders and implants go underneath the muscle, and some -- if not all -- of the skin is saved for the reconstruction, a three-month process, she said.
"So when you wake up after the first surgery, it's not your final outcome and your final volume. It's not completely flat in what we otherwise would have without a reconstruction," Ochoa said. "They gradually fill up the expander, get up to the size that you're ultimately shooting for, and then there's a second surgery where they come in, switch out the expander to the permanent implant. The permanent implant is when you pick whether you want saline or silicone, kind of what size you're shooting for."
At UAMS, surgeons perform preventive mastectomies, but more often than not, patients find out they have the BRCA gene once they have already been diagnosed with breast cancer, Ochoa said. She added that most cancer patients end up with the disease because of either bad luck or environmental factors, not for hereditary reasons.
Lesley Murphy woke up around 3 p.m. April 11, after some seven hours in surgery. She vividly remembered -- "how could I forget the feeling" -- first feeling pain when she was moved from one bed to another.
"Realization set in on what road was ahead," she said. "I remember my dad was driving me home from the hospital the day after surgery, and I was so nervous because even in the wheelchair from my hospital room to [the first floor], every little crack you would go over, you would feel it."
Her mom, who had been by her side through all the doctor appointments, slept by her side for the first couple of nights. She couldn't sit up in bed or easily get up to use the bathroom. She needed help getting dressed in the mornings. She didn't like being in the same position for too long.
But, day by day, she started to feel more normal.
By May 6, she was lying on her stomach, spending time in the sun and working out, though, she said, she may have cheated on the last one by a bit.
And on May 11 -- a month after her surgery -- she posted on social media a thank-you note to her supporters, who she said helped ease her recovery, and wrote that she hoped she has helped others in a similar situation.
"Knowledge really is power," she said in an earlier interview. "It's been a wash of emotions, but I think this is a story of empowerment."
Metro on 05/28/2017
Read the original here:
One genetic test transforms a life - Arkansas Online
- BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - February 13th, 2023 [February 13th, 2023]
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day - Marketscreener.com - February 7th, 2023 [February 7th, 2023]
- Gene | Definition, Structure, Expression, & Facts | Britannica - January 27th, 2023 [January 27th, 2023]
- New gene therapy delivers treatment directly to brain - January 27th, 2023 [January 27th, 2023]
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 25th, 2023 [January 25th, 2023]
- A blood test that identifies people at higher risk of miscarriage? Thats the goal of this award-winning Rutgers med student. - The Philadelphia... - January 19th, 2023 [January 19th, 2023]
- Gene Therapy: Genes As Medicine | Pfizer - January 6th, 2023 [January 6th, 2023]
- How Genomics will ensure a risk-free and beneficial treatment for good health and well-being - The Financial Express - December 28th, 2022 [December 28th, 2022]
- Regenerative Medicine Advanced Therapy Designation | FDA - December 18th, 2022 [December 18th, 2022]
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022 [November 23rd, 2022]
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022 [October 17th, 2022]
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022 [October 17th, 2022]
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022 [October 17th, 2022]
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022 [October 17th, 2022]
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022 [October 17th, 2022]
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022 [October 17th, 2022]
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022 [October 17th, 2022]
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022 [October 17th, 2022]
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022 [October 17th, 2022]
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022 [October 17th, 2022]
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022 [October 17th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022 [October 17th, 2022]
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022 [October 17th, 2022]
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022 [October 17th, 2022]
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022 [October 17th, 2022]
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022 [October 17th, 2022]
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022 [October 17th, 2022]
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022 [October 17th, 2022]
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022 [October 11th, 2022]
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022 [October 11th, 2022]
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022 [October 11th, 2022]
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022 [October 11th, 2022]
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022 [October 11th, 2022]
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022 [October 11th, 2022]
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022 [October 8th, 2022]
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022 [October 8th, 2022]
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022 [October 8th, 2022]
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022 [October 8th, 2022]
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022 [October 8th, 2022]
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022 [October 8th, 2022]
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022 [October 8th, 2022]
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022 [October 8th, 2022]
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022 [October 2nd, 2022]
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022 [October 2nd, 2022]
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022 [October 2nd, 2022]
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022 [October 2nd, 2022]
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022 [October 2nd, 2022]
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022 [October 2nd, 2022]
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022 [October 2nd, 2022]
- Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC - October 2nd, 2022 [October 2nd, 2022]
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022 [October 2nd, 2022]
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022 [October 2nd, 2022]
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022 [October 2nd, 2022]
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022 [October 2nd, 2022]
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022 [October 2nd, 2022]
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022 [October 2nd, 2022]
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022 [September 20th, 2022]
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022 [September 20th, 2022]
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022 [September 20th, 2022]
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022 [September 20th, 2022]
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022 [September 20th, 2022]
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022 [September 20th, 2022]
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022 [September 20th, 2022]
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022 [September 20th, 2022]
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022 [September 20th, 2022]
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022 [September 20th, 2022]
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022 [September 20th, 2022]
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022 [September 20th, 2022]
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022 [September 20th, 2022]
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022 [September 20th, 2022]
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022 [September 14th, 2022]